Clinical Trials Browser

Phase 2/3 × Mastocytosis, Systemic × 90 days × Clear all

NCT04910685 2026-05-22

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Phase 2/3 Recruiting

Mastocytosis, Systemic